Researchers Link Smoking to Raised Pancreatic Cancer Risk, Urge Closer Screening for Smokers

U.S. researchers say smoking may substantially raise the risk of pancreatic cancer and are urging general practitioners to screen smokers more closely, citing a newly identified cellular response to tobacco toxins that could help explain the link.

In a study published in the journal Cancer Discovery, investigators at the University of Michigan Health Rogel Cancer Center reported finding a specific cell type that appears to respond to cancer-causing compounds found in cigarettes. Lead author Professor Timothy Frankel, a surgical oncologist, said the findings suggest smokers who develop pancreatic cancer may need different clinical management and called for greater vigilance by primary care doctors.

"There's a potential that we need to treat smokers who develop pancreatic cancer differently," Frankel said. "There is not a great screening mechanism, but people who smoke should be educated about symptoms to look out for and consider referrals to a high-risk clinic."

Pancreatic cancer is often described as a "silent killer" because its early symptoms can be subtle and easily mistaken for other conditions, and it is frequently diagnosed at an advanced stage. The disease kills just over 10,000 patients every year, about one death every hour, and researchers and health agencies warn incidence is expected to rise in the coming decades. Projections cited in reporting around the study forecast roughly 201,000 cases of pancreatic cancer by 2040.

The Michigan team reported that exposure to cigarette-related carcinogens provokes changes in a cell population within the pancreas, a finding that may help explain how tobacco use contributes to cancer development. The researchers say the cell’s response could be a target for future efforts to detect or interrupt carcinogenic progression, although they caution that the current work does not establish immediate changes to clinical screening protocols.

Clinicians and the study authors emphasized that no widely effective population-level screening test for pancreatic cancer currently exists. That limitation, they said, makes early detection challenging and places greater emphasis on preventing known risk factors and educating high-risk groups.

Common early warning signs of pancreatic cancer include unexplained weight loss, abdominal or back pain, jaundice, changes in stool, and new-onset diabetes, according to clinicians and cancer organizations. Because those symptoms overlap with many benign conditions, the authors recommended that smokers be advised about these clinical red flags and that primary care clinicians consider prompt referral to specialty or high-risk clinics when concern arises.

Public health specialists noted that smoking is a modifiable risk factor and said the findings add to a substantial body of evidence linking tobacco use to multiple cancers and other serious diseases. They urged continued emphasis on smoking cessation programmes as a primary prevention strategy while researchers pursue better screening methods and biomarkers that could identify pancreatic cancer earlier.

The study’s authors and outside experts also called for further research to validate the cellular findings in larger human studies, clarify how cigarette toxins interact with pancreatic tissue over time, and determine whether targeted surveillance of smokers can be implemented in ways that improve outcomes without creating excessive false positives or unnecessary interventions.

Until more definitive screening tools are available, clinicians and public health officials said the priority should remain on reducing tobacco use, raising awareness of pancreatic cancer symptoms among people who smoke, and ensuring rapid evaluation of concerning signs. The researchers said their findings provide a biological clue that could guide future efforts to detect and treat pancreatic cancer earlier among those with tobacco exposure.